SCHEMBL5534846

SCHEMBL5534846

[CH2]c1ccc2c(c1)CCC(=O)N2CC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.68
CYP1A2 P05177 1/20 0.54
CYP11B1 P15538 1/20 0.54
CYP11B2 P19099 1/20 0.54
HDAC1 Q13547 4/20 0.41
HDAC8 Q9BY41 4/20 0.41
HDAC6 Q9UBN7 4/20 0.41
BRD4 O60885 1/20 0.41
POLB P06746 3/20 0.40
CHRM1 P11229 4/20 0.39
CHRM2 P08172 3/20 0.39
CHRM4 P08173 3/20 0.39
CHRM5 P08912 3/20 0.39
DRD2 P14416 3/20 0.39
CHRM3 P20309 3/20 0.39
DRD4 P21917 3/20 0.39
DRD3 P35462 3/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MET P08581 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539807 0.88 ATAD2 (0.52) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL5544590 0.85 CHRM1 (0.56) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL5542098 0.84 CHRM1 (0.52) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL5537268 0.83 CHRM1 (0.51) ATAD2CHRM1CHRM2CHRM4CHRM5
SCHEMBL435242 0.82 ATAD2 (0.69) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL8553331 0.81 ATAD2 (0.68) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL8138675 0.81 ATAD2 (1.00) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL1119384 0.81 ATAD2 (0.68) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL13340814 0.78 ATAD2 (0.64) ATAD2CYP1A2CYP11B1CYP11B2HDAC1
SCHEMBL5543650 0.78 CYP11B2 (0.51) ATAD2CYP1A2CYP11B1CYP11B2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ATAD2 1255/4885CYP1A2 659/4885CYP11B1 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.